바이오인

 

For the last three years, our Point of view articles have ed heavily on matters of efficiency - the need to do more with less and the measures companies and investors are undertaking to conduct research and development (R&D) more efficiently. This was only natural. After all, capital efficiency was the topmost concern for industry leaders in the aftermath of the global financial crisis, when a “new normal” emerged for capital markets, characterized by restricted access to funding for smaller
companies.

We reviewed in some detail the steps venture capitalists and companies are taking - models such as fail-fast R&D, asset-centric funding and more. While these creative approaches are much needed, they are, as we pointed out in last year’s report, tinkering around the edges of an existing R&D paradigm that is now under unprecedented strain.

Last year, we discussed a model that could radically R&D by taking a much more holistic approach to drug development, sharing information to learn in real time across the cycle of care and fundamentally changing how risk and reward are allocated. This approach, the holistic open learning network, or HOLNet, involves a broad spectrum of entities (biotech and pharma companies, payers, providers, disease foundations and potentially others) collaborating in “precompetitive” spaces to share data and establish standards. We continue to think that these consortia have the potential to the R&D paradigm from one that is linear, slow, inflexible, expensive and siloed to one that is iterative, fast, adaptive, costefficient and open/networked.

 

 

......(계속)